Barclays Upgrades Arcturus Therapeutics (ARCT) to Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ARCT Hot Sheet
Price: $10.87 +13.94%
Rating Summary:
14 Buy, 4 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
14 Buy, 4 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Barclays analyst Gena Wang upgraded Arcturus Therapeutics (NASDAQ: ARCT) from Underweight to Equalweight with a price target of $25.00 (from $16.00).
For an analyst ratings summary and ratings history on Arcturus Therapeutics click here. For more ratings news on Arcturus Therapeutics click here.
Shares of Arcturus Therapeutics closed at $18.28 yesterday.
You May Also Be Interested In
- Northland Upgrades Astera Labs (ALAB) to Outperform
- Nomad Foods Ltd (NOMD) PT Raised to $15 at Jefferies
- Kotak Upgrades Mahanagar Gas Limited (MAHGL:IN) to Add (2)
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
